Rx License-Rx

TAB-4275

Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276

Summary: The National Cancer Institute (NCI) seeks research collaborations and/or licensees for the development of a CD276 antibody drug conjugate (ADC) for the treatment of solid tumors. Description of Technology: Angiogenesis is the formation of new blood vessels from pre-existing blood vessels. Angiogenesis occurs during normal growth and development (physiological angiogenesis) and during the growth of solid tumors (pathological angiogenesis). CD276, also known as B7-H3, is a cell surface tumor endothelial marker that is highly expressed in the tumor vessels of human lung, breast, colon, endometrial, renal, and ovarian cancer, but not in the angiogenic vessels of normal, healthy tissue. This differential expression makes CD276 an attractive target for cancer treatment due to the ability to selectively target pathological angiogenesis without impacting physiological angiogenesis. In fact, CD276-directed therapeutic antibodies may...

Intelligence Memo

Owner: National Institutes of Health

Core category: Therapeutics

Therapeutic area: Oncology

Indication: Oncology

Modality: Biologic

Focus tags: Oncology, Immunology, Cardiometabolic

Technology tags: Biologic, Drug Delivery, Diagnostic / Biomarker

Mechanism:

Development stage: Preclinical

Patent status: Abandoned; Expired; Pending; Issued

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Oncology. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be preclinical and is associated with National Institutes of Health. The practical first use case is Oncology. Public description: Summary: The National Cancer Institute (NCI) seeks research collaborations and/or licensees for the development of a CD276 antibody drug conjugate (ADC) for the treatment of solid tumors. Description of Technology: Angiogenesis is the.

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

Oncology remains highly partnerable: Pharma buyers still pay attention when an asset can be tied to biomarkers, combinations, resistance biology, or a defined tumor segment.

Can sell into pharma before reimbursement: A biomarker or AI tool can create value as trial enrichment, patient stratification, or translational support before becoming a regulated diagnostic.

Delivery can refresh known biology: A better route, depot, local exposure profile, or targeted formulation can create new IP and reduce systemic risk around existing mechanisms.

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

Validation can be harder than the demo: Models and biomarkers need locked datasets, external validation, clinical utility, data rights, and a regulatory/reimbursement plan.

Exposure advantage must be real: Delivery stories fail when biodistribution, local tolerability, stability, or payload compatibility does not beat simpler alternatives.

Competitive field may be crowded: Oncology buyers will ask why this is better than existing modalities, combinations, and biomarker strategies already in the clinic.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Oncology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets Merck — Checkpoint-franchise adjacency and combination-trial appetite. AstraZeneca — Oncology breadth plus interest in biomarker-defined populations. Roche / Genentech — Diagnostics plus oncology translational machinery.

Development Strategy to Increase PoS

First indication: Oncology

Study design: Retrospective locked-dataset validation followed by one prospective pharma enrichment pilot.

Key experiments Validate the AI-optimized pivot: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed: Strong enough to test buyer appetite now while validating the cheapest decisive experiment. The most investable version is: Monetize first as a pharma enrichment engine, not a reimbursed diagnostic

Best next experiment: Run the smallest independent study that validates: Package the model or assay with a locked validation dataset, CLIA/service workflow, and one sponsor-ready use case.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.